Suchergebnisse - "Buti, Maria"

PubPharm (34)

1

Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2019

von Marcellin, P. | Wong, D. | Sievert, W. | +14

2

Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy : a prespecified follow-up analysis of two randomised trials

enthalten in: The lancet. Gastroenterology & hepatology | 2019

von Buti, M. | Wong, D. | Gane, E. | +11

CommentIn: Lancet Gastroenterol Hepatol. 2019 Apr;4(4):260-262. - PMID 30795959

3

Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a : Week 120 Analysis

enthalten in: Digestive diseases and sciences | 2018

von Ahn, S. | Marcellin, P. | Ma, X. | +19

ErratumIn: Dig Dis Sci. 2018 Oct 15;:. - PMID 30324553

4

No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection

enthalten in: Antimicrobial agents and chemotherapy | 2018

von Cathcart, A. | Chan, H. | Bhardwaj, N. | +16

5

Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population

enthalten in: Journal of hepatology | 2018

von Papatheodoridis, G. | Sypsa, V. | Dalekos, G. | +24

6

96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection

enthalten in: Journal of hepatology | 2018

von Agarwal, K. | Brunetto, M. | Seto, W. | +28

7

Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2018

von Buti, M. | Riveiro-Barciela, M. | Esteban, R.

8

Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B

enthalten in: Gut | 2017

von Bayliss, J. | Yuen, L. | Rosenberg, G. | +17

CommentIn: Gut. 2017 Jul;66(7):1349. - PMID 27797942

9

Tenofovir Alafenamide Fumarate : A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection

enthalten in: The Journal of infectious diseases | 2017

von Buti, M. | Riveiro-Barciela, M. | Esteban, R.

10

The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B

enthalten in: Hepatology (Baltimore, Md.) | 2017

von Papatheodoridis, G. | Idilman, R. | Dalekos, G. | +24

CommentIn: Hepatobiliary Surg Nutr. 2018 Jun;7(3):212-213. - PMID 30046577